论文部分内容阅读
《新财经》本期以“中国资本药局”为题,目的是寻找中国医药业并购浪潮中更具活力的主导力量。《新财经》选择了近年来具有典型代表性的几个并购案例——西安东盛、太太药业、复星实业,并深入剖析其并购手法、并购理念以及并购效果。通过研究,《新财经》认为,中国医药类企业(尤其公众企业——上市公司)在追求规模、投资收益的同时,还需对并购后企业之间整合、发挥协同效应给予更多的关注。 另外,《新财经》本期还关注了天士力、迪康集团、片仔癀等几家医药类公司,它们在资本与产业双线发展的过程中,各自处于不同的阶段,未来将面临不同的难题。
In this issue of “New Finance and Economics”, the title is “China Capital Pharmacy,” with the purpose of finding a more dynamic leading force in the wave of mergers and acquisitions in China’s pharmaceutical industry. “New Finance” chose several representative cases of mergers and acquisitions in recent years - Xi’an Dongsheng, Wife, Fosun Industries, and in-depth analysis of its mergers and acquisitions, the concept of mergers and acquisitions and the effect of mergers and acquisitions. Through research, “New Finance” believes that Chinese pharmaceutical enterprises (especially public enterprises - listed companies) should pay more attention to the integration and synergies between enterprises after the mergers and acquisitions while pursuing the scale and investment returns. In addition, New Finance also paid attention to several pharmaceutical companies such as Tasly, Dikang Group and Pien Tze Huang in their respective phases in the dual development of capital and industry and faced different challenges in the future.